

**Please read the package leaflet that comes with your medicine for further information.**

**If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet.**

**You can also report side effects directly via**

Sandoz Pharmaceuticals d.d.  
Verovskova 57  
SI-1000 Ljubljana  
Slovenia  
Tel: +35699644126

**Marketing Authorization Holder:**

Sandoz GmbH  
Biochemiestr. 10  
6250 Kundl, Austria

**Local Distributor:**

V.J. Salomone Pharma Limited  
Upper Cross Road, Marsa, MRS 1542, Malta

**By reporting side effects, you can help provide more information on the safety of **Jubbonti**.**

**This reminder card contains important safety information that you need to be aware of before and during treatment with denosumab (▼**Jubbonti**).**

**SANDOZ**

▼ *This medicine is subject to additional monitoring.  
This will allow quick identification of new safety information.  
You can help by reporting any side effects you may get.  
See the end of the card for how to report side effects*

Version 1.0 / 21 May 2024

HAs approval: May 13.2026

Your doctor has recommended that you receive denosumab ([Jubbonti](#)), which is used to treat osteoporosis and bone loss. These diseases involve thinning and weakening of the bones so they may break more easily.

A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported rarely (may affect up to 1 in 1,000 people) in patients receiving [Jubbonti](#) for osteoporosis. ONJ can also occur after stopping treatment.

It is important to try to prevent ONJ developing as it may be a painful condition that can be difficult to treat. To reduce the risk for ONJ, there are some precautions you should take.

**Before starting treatment:**

Tell your doctor/nurse (health care professional) if you have any problems with your mouth or teeth.

Your doctor may ask you to undergo a dental examination if you:

- were previously treated with another medication being a bisphosphonate
- are taking medicines called corticosteroids (such as prednisolone or dexamethasone)
- are a smoker
- have cancer
- have not had a dental check up for a long time
- have problems with your mouth or teeth

**While being treated:**

- You should maintain good oral hygiene and receive routine dental check-ups. If you wear dentures you should make sure these fit properly.
- If you are under dental treatment or will undergo dental surgery (e.g., tooth extractions), inform your doctor and tell your dentist that you are being treated with [Jubbonti](#).
- Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of osteonecrosis of the jaw.

HAs approval: May 13.2026

Suspected adverse reactions and medication errors associated with the use of **Jubbonti** should be reported using the Medicines Authority ADR reporting form, which is available online at <http://www.medicinesauthority.gov.mt/adrportal> and sent by post or email to:

**Post:**

Pharmacovigilance Section at Post-Licensing Directorate,  
Malta Medicines Authority,  
Sir Temi Zammit Buildings,  
Malta Life Sciences Park,  
San Gwann SGN 3000

**E-mail:**

[postlicensing.medicinesauthority@gov.mt](mailto:postlicensing.medicinesauthority@gov.mt)

Alternatively at:

Sandoz Pharmaceuticals d.d.  
Verovskova 57  
SI-1000 Ljubljana  
Slovenia  
Tel: +35699644126

**Marketing Authorization Holder:**

Sandoz GmbH  
Biochemiestr. 10  
6250 Kundl, Austria

**Local Distributor:**

V.J. Salomone Pharma Limited  
Upper Cross Road, Marsa, MRS 1542, Malta

Jubbonti/RMP v. 1.1/April 2026/GR2604237754

HAs approval: May 13.2026